209746-55-4

Upstream product

• 1634-34-0 2',6'-dihydroxy-4'-methylacetophenone 
• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 13444-19-4 2,4-diacetyl-5-methyl-resorcinol 
• 23616-79-7 benzyltri(n-butyl)ammonium chloride 
• 20982-28-9 5-methylbenzene-1,3-diyl diacetate 
• 504-15-4 orcinol 
• 889140-51-6 orcinol monoacetate 

Downstream Products

• 1049661-85-9 (E)-3-Benzofuran-5-yl-1-[2-hydroxy-4-methyl-6-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-phenyl]-propenone 
• 209746-56-5 3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-β-D-glucopyranoside 
• 209746-77-0 3-(benzo[b]furan-5-yl)-6'-tert-butyldimethylsilyloxy-2'-hydroxy-4'-methylpropiophenone 2'-O-(2-O-acetyl-4,6-O-benzylidene-3-O-tert-butyldimethylsilyl-β-D-glucopyranoside) 
• 209746-76-9 3-(benzo[b]furan-5-yl)-6'-tert-butyldimethylsilyloxy-2'-hydroxy-4'-methylpropiophenone 2'-O-(4,6-O-benzylidene-3-O-tert-butyldimethylsilyl-β-D-glucopyranoside) 
• 209746-80-5 6'-acetoxy-3-(benzo[b]furan-5-yl)-2'-hydroxy-4'-methylpropiophenone 2'-O-(2,3-O-diacetyl-4,6-O-benzylidene-β-D-glucopyranoside) 
• 209746-65-6 Carbonic acid (2R,3S,4S,5R,6S)-6-[3-allyloxy-2-(3-benzofuran-5-yl-propionyl)-5-methyl-phenoxy]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl ester 2-methoxy-ethyl ester 
• 209746-82-7 3-(benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-(2,3-O-diacetyl-4,6-O-benzylidene-β-D-glucopyranoside) 
• 209746-60-1 Carbonic acid (2R,3S,4S,5R,6S)-6-[3-allyloxy-2-(3-benzofuran-5-yl-propionyl)-5-methyl-phenoxy]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl ester ethyl ester 
• 209746-66-7 Methoxy-acetic acid (2R,3S,4S,5R,6S)-6-[3-allyloxy-2-(3-benzofuran-5-yl-propionyl)-5-methyl-phenoxy]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl ester 
• 209746-62-3 Carbonic acid (2R,3S,4S,5R,6S)-6-[3-allyloxy-2-(3-benzofuran-5-yl-propionyl)-5-methyl-phenoxy]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl ester isopropyl ester 
• 209746-64-5 Acetic acid (2R,3S,4S,5R,6S)-6-[3-allyloxy-2-(3-benzofuran-5-yl-propionyl)-5-methyl-phenoxy]-3,4,5-trihydroxy-tetrahydro-pyran-2-ylmethyl ester 
• 209746-58-7 3-(5-benzo[b]furanyl)-2'-(6-O-methoxycarbonyl-β-D-glucopyranosyloxy)-6'-allyloxy-4'-methylpropiophenone 

Relevant academic research and scientific papers

FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF

The present invention provides fused heterocyclic derivatives represented by the general formula: wherein R1 represents H, halogen, OH, etc.; R2 represents H, halogen or an alkyl group; R3 and R4 represent H, OH, halogen, etc.; Q represents alkylene, etc.; ring A represents aryl or heteroaryl; and G represents or ???or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors

A series of glucose conjugates was synthesized and tested for inhibition of SGLT1 and SGLT2.

Propiophenone derivatives and process for preparing the same

A propiophenone derivative of the formula (I): wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a beta -D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected, or a pharmace

Na+-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'- dehydroxyphlorizin derivatives substituted on the B ring

In our studies of Na+-glucose cotransporter (SGLT) inhibitors as antidiabetic agents, a series of novel 4'- dehydroxyphlorizin derivatives substituted on the B ring was prepared and their effects on urinary glucose excretion were evaluated in rats. Introduction of only a small alkyl group at the 4'-position increased the activity, and 3-(benzo[b]furan-5- yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O-β-D- glucopyranoside (4) showed the most potent effect. To overcome hydrolysis of compound 4 by β-glucosidase in the digestive tract, the OH groups on the glucose moiety of compound 4 were modified. Three prodrugs (5, 42, and 55) were more potent than the parent compound 4 by oral administration, and finally 3- (benzo[b]furan-5-yl)-2',6'-dihydroxy-4'-methylpropiophenone 2'-O- (6-O-methoxycarbonyl-β-D-glucopyranoside) (5) was selected as a new promising candidate. Compound 5 was metabolized mainly by liver esterase to the active form (4), which was about 10 times more potent than 5 in inhibiting SGLT. In oral glucose tolerance test in db/db mice, compound 5 dose-dependently suppressed the elevation of glucose levels. Single administration of 5 reduced hyperglycemia concurrently with increase of glucose excretion into urine in diabetic KK-A(y) mice. Furthermore, compound 5 suppressed the elevation of blood glucose levels but did not lower it below the normal level even in fasted conditions in KK- A(y) mice. Additionally, long-term treatment with 5 dose- dependently reduced hyperglycemia and HbA1c in KK-A(y) mice. These pharmacological data strongly suggest that compound 5 has a therapeutic potential in the treatment of NIDDM.